Literature DB >> 15233737

Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications.

Sandip K Datta1, Hearn J Cho, Kenji Takabayashi, Anthony A Horner, Eyal Raz.   

Abstract

Conjugation of protein antigen with immunostimulatory oligonucleotides creates a potent immunogen. Physical linking of oligonucleotides to antigen enhances antigen uptake and targets the adjuvant properties of the oligonucleotides to the antigen-presenting cell. In addition, the conjugated oligonucleotides appear to have improved immunostimulatory abilities compared to free oligonucleotides, presumably due to enhanced activation of Toll-like receptor 9. Immunization with these conjugate preparations elicits antigen-specific antibody responses, a T-helper cell 1-biased cytokine profile from CD4 T cells, and CD8 cytotoxic T-lymphocyte activity that is CD4 independent. The humoral and cellular immune responses induced by these conjugates suggest they can be used to create effective vaccines against infectious pathogens and tumors and to beneficially modulate allergic responses. Indeed, recent clinical trial data show symptom relief and immunomodulation of the allergic response in patients with allergic rhinitis. This review considers the mechanisms of action of antigen-oligonucleotide conjugates and discusses available data regarding their use for the prevention and treatment of infectious, oncologic, and allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233737     DOI: 10.1111/j.0105-2896.2004.00149.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  12 in total

Review 1.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

3.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

Review 4.  Induction of antigen cross-presentation by Toll-like receptors.

Authors:  Sandip K Datta; Eyal Raz
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

5.  Recent advances in immunotherapy of allergic rhinitis.

Authors:  Chul Hee Lee; Ji-Hun Mo
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

6.  Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.

Authors:  Abu-Baker M Abdel-Aal; Vani Lakshminarayanan; Pamela Thompson; Nitin Supekar; Judy M Bradley; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2014-05-30       Impact factor: 3.164

7.  Extended sequence preferences for oligodeoxyribonucleotide activity.

Authors:  Petar Lenert; Adam J Goeken; Robert F Ashman
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

8.  In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines.

Authors:  Tristan T Beaudette; Eric M Bachelder; Joel A Cohen; Allie C Obermeyer; Kyle E Broaders; Jean M J Fréchet; Eun-Suk Kang; Ines Mende; William W Tseng; Matthew G Davidson; Edgar G Engleman
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

9.  Nucleic acid-mediated intracellular protein delivery by lipid-like nanoparticles.

Authors:  Ahmed A Eltoukhy; Delai Chen; Omid Veiseh; Jeisa M Pelet; Hao Yin; Yizhou Dong; Daniel G Anderson
Journal:  Biomaterials       Date:  2014-05-13       Impact factor: 12.479

Review 10.  Guiding principles in the design of molecular bioconjugates for vaccine applications.

Authors:  Haipeng Liu; Darrell J Irvine
Journal:  Bioconjug Chem       Date:  2015-04-16       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.